154 related articles for article (PubMed ID: 11160641)
21. Selective inhibition of methoxyflavonoids on human CYP1B1 activity.
Takemura H; Itoh T; Yamamoto K; Sakakibara H; Shimoi K
Bioorg Med Chem; 2010 Sep; 18(17):6310-5. PubMed ID: 20696580
[TBL] [Abstract][Full Text] [Related]
22. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes.
Foroozesh M; Primrose G; Guo Z; Bell LC; Alworth WL; Guengerich FP
Chem Res Toxicol; 1997 Jan; 10(1):91-102. PubMed ID: 9074808
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome P450 1B1: a novel anticancer therapeutic target.
McFadyen MC; Murray GI
Future Oncol; 2005 Apr; 1(2):259-63. PubMed ID: 16555997
[TBL] [Abstract][Full Text] [Related]
24. P450 enzyme expression patterns in the NCI human tumor cell line panel.
Yu LJ; Matias J; Scudiero DA; Hite KM; Monks A; Sausville EA; Waxman DJ
Drug Metab Dispos; 2001 Mar; 29(3):304-12. PubMed ID: 11181500
[TBL] [Abstract][Full Text] [Related]
25. Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1.
Choudhary D; Jansson I; Stoilov I; Sarfarazi M; Schenkman JB
Drug Metab Dispos; 2004 Aug; 32(8):840-7. PubMed ID: 15258110
[TBL] [Abstract][Full Text] [Related]
26. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1.
Murray GI; Melvin WT; Greenlee WF; Burke MD
Annu Rev Pharmacol Toxicol; 2001; 41():297-316. PubMed ID: 11264459
[TBL] [Abstract][Full Text] [Related]
27. The Effect of Oxidation on Berberine-Mediated CYP1 Inhibition: Oxidation Behavior and Metabolite-Mediated Inhibition.
Lo SN; Shen CC; Chang CY; Tsai KC; Huang CC; Wu TS; Ueng YF
Drug Metab Dispos; 2015 Jul; 43(7):1100-7. PubMed ID: 25953522
[TBL] [Abstract][Full Text] [Related]
28. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1.
Potter GA; Patterson LH; Wanogho E; Perry PJ; Butler PC; Ijaz T; Ruparelia KC; Lamb JH; Farmer PB; Stanley LA; Burke MD
Br J Cancer; 2002 Mar; 86(5):774-8. PubMed ID: 11875742
[TBL] [Abstract][Full Text] [Related]
29. Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents.
Chun YJ; Kim S
Med Res Rev; 2003 Nov; 23(6):657-68. PubMed ID: 12939788
[TBL] [Abstract][Full Text] [Related]
30. Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites.
Chang YP; Huang CC; Shen CC; Tsai KC; Ueng YF
Drug Metab Pharmacokinet; 2015 Oct; 30(5):374-83. PubMed ID: 26403084
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention.
Sissung TM; Price DK; Sparreboom A; Figg WD
Mol Cancer Res; 2006 Mar; 4(3):135-50. PubMed ID: 16547151
[TBL] [Abstract][Full Text] [Related]
32. Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer cells due to CYP1 activation.
Androutsopoulos VP; Mahale S; Arroo RR; Potter G
Oncol Rep; 2009 Jun; 21(6):1525-8. PubMed ID: 19424633
[TBL] [Abstract][Full Text] [Related]
33. Modulation of cytochrome P450 activity: implications for cancer therapy.
Scripture CD; Sparreboom A; Figg WD
Lancet Oncol; 2005 Oct; 6(10):780-9. PubMed ID: 16198984
[TBL] [Abstract][Full Text] [Related]
34. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.
Kivistö KT; Kroemer HK; Eichelbaum M
Br J Clin Pharmacol; 1995 Dec; 40(6):523-30. PubMed ID: 8703657
[TBL] [Abstract][Full Text] [Related]
35. CYP1B1: A Promising Target in Cancer Drug Discovery.
Fabris M; Luiza Silva M; de Santiago-Silva KM; de Lima Ferreira Bispo M; Goes Camargo P
Anticancer Agents Med Chem; 2023; 23(9):981-988. PubMed ID: 36655529
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of cytochrome P450 (CYP) 1B1.
Dutour R; Poirier D
Eur J Med Chem; 2017 Jul; 135():296-306. PubMed ID: 28458135
[TBL] [Abstract][Full Text] [Related]
37. A 3D model of CYP1B1 explains the dominant 4-hydroxylation of estradiol.
Itoh T; Takemura H; Shimoi K; Yamamoto K
J Chem Inf Model; 2010 Jun; 50(6):1173-8. PubMed ID: 20462226
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450 CYP1B1 activity in renal cell carcinoma.
McFadyen MC; Melvin WT; Murray GI
Br J Cancer; 2004 Aug; 91(5):966-71. PubMed ID: 15280921
[TBL] [Abstract][Full Text] [Related]
39. Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression.
Cui J; Meng Q; Zhang X; Cui Q; Zhou W; Li S
J Med Chem; 2015 Apr; 58(8):3534-47. PubMed ID: 25799264
[TBL] [Abstract][Full Text] [Related]
40. Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development.
Gibson P; Gill JH; Khan PA; Seargent JM; Martin SW; Batman PA; Griffith J; Bradley C; Double JA; Bibby MC; Loadman PM
Mol Cancer Ther; 2003 Jun; 2(6):527-34. PubMed ID: 12813131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
